Patents by Inventor Luisa Maria Martin-Cabrejas

Luisa Maria Martin-Cabrejas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7767674
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: August 3, 2010
    Assignee: Eli Lilly and Company
    Inventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Yong Wang, Boyu Zhong, Jesus Andres Blas, Alfonso De Dios, Beatriz Lopez De Uralde-Garmendia, Luisa Maria Martin Cabrejas
  • Publication number: 20090118323
    Abstract: The present invention provides antitumor compounds of the formula (I); and antitumor methods.
    Type: Application
    Filed: September 11, 2007
    Publication date: May 7, 2009
    Inventors: Mary Margaret Mader, Luisa Maria Martin-Cabrejas, Michael Enrico Richett
  • Publication number: 20080306068
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Application
    Filed: June 15, 2005
    Publication date: December 11, 2008
    Applicant: Eli Lilly and Company
    Inventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Yong Wang, Boyu Zhong, Jesus Andres Blas, Alfonso De Dios, Beatriz Lopez De Uralde-Garmendia, Luisa Maria Martin Cabrejas
  • Patent number: 7320995
    Abstract: The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: January 22, 2008
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jose Eugenio De Diego Gomez, Alfonso De Dios, Chafiq Hamdouchi Hamdouchi, Tiecho Li, Beatriz Lopez De Uralde Garmendia, Michal Vieth, Jeremy Schulenberg York, Robert Dean Dally, Miriam Filadelfa Del Prado Catalina, Carlos Jaramillo Aguado, Luisa Maria Martin-Cabrejas, Carlos Montero Salgado, Sheila Pleite Selgas, Concepcion Sanchez-Martinez, Timothy Alan Shepherd, James Howard Wikel
  • Patent number: 7282595
    Abstract: The present invention provides antitumor compounds of the formula (I); and antitumor methods.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: October 16, 2007
    Assignee: Eli Lilly and Company
    Inventors: Mary Margaret Mader, Luisa Maria Martin-Cabrejas, Michael Enrico Richett
  • Patent number: 7125871
    Abstract: Compounds of the formula (I) in which R1, R2 and X1 have the meanings given in the specification, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: October 24, 2006
    Assignee: Eli Lilly and Company
    Inventors: Ivan Collado Cano, Jesus Ezquerra-Carrera, Alicia Marcos Liorente, Luisa Maria Martin-Cabrejas, James Allen Monn
  • Patent number: 7038077
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: May 2, 2006
    Assignee: Eli Lilly and Company
    Inventors: Anne Hollins Dantzig, James Allen Monn, Stephanie Ann Sweetana, Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Marc Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Carlos Montero Salgado, Concepcion Pedregal-Tercero
  • Publication number: 20040248963
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs of formula (I) wherein the residues R11, R12 and R13 are as defined in claim 1. The invention further relates to processes for the preparation of the compounds of formula (I), and to pharmaceutical compositions for the treatment of neurological and psychiatric disorders comprising said compounds.
    Type: Application
    Filed: April 30, 2004
    Publication date: December 9, 2004
    Inventors: Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Mark Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Steven Marc Massey, James Allen Monn, Carlos Montero Salgado, Concepcion Pedregal-Tercero, Matthew John Valli
  • Publication number: 20040176459
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: December 10, 2003
    Publication date: September 9, 2004
    Inventors: Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Carlos Montero Salgado, Concepcion Pedregal-Tercero, Rafael Ferritto Crespo, Marc Francis Herin, Maria Angeles Martinez-Grau, Steven Marc Massey, James Allen Monn, Matthew John Valli
  • Publication number: 20040138304
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: January 26, 2004
    Publication date: July 15, 2004
    Inventors: Anne Hollins Dantzig, James Allen Monn, Stephanie Ann Sweetana, Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Marc Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Carlos Montero Salgado, Concepcion Pedregal-Tercero
  • Publication number: 20040092553
    Abstract: Compounds of the formula (I) in which R1, R2 and X1 have the meanings given in the specification, modulate metabotopic glotamate receptor function and are useful in treating disorders of the central nervous system.
    Type: Application
    Filed: June 6, 2003
    Publication date: May 13, 2004
    Inventors: Ivan Collado Cano, Jesus Ezguera-Carrera, Alicia Marcos Liorente, Luisa Maria Martin-Cabrejas, James Allen Monn